// App-Quantinova.ai

: Costarting Sitagliptin with Metformin Is Associated with a Lower Likelihood of Disease Progression in Newly Treated Patients with Type 2 Diabetes

Researchers

Presenter

  • SCOTT A. CAMPBELL

Principal Investigators

  • PETER E. LIGHT

Medical Centers

  • N/A

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

Disease

  • Type 2 diabetes mellitus

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • Sitagliptin

  • Metformin Hydrochloride

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved